Understanding what drives breast tumor progression is of utmost importance for blocking tumor metastasis; we have identified that semaphorin 7a is a potent driver of ductal carcinoma in situ (DCIS) progression. Semaphorin 7a is a glycophosphatidylinositol membrane-anchored protein that promotes attachment and spreading in multiple cell types. Here, we show that increased expression of SEMA7A occurs in a large percentage of breast cancers and is associated with decreased overall and distant metastasis-free survival. In both in vitro and in vivo models, short hairpin-mediated silencing of SEMA7A reveals roles for semaphorin 7a in the promotion of DCIS growth, motility and invasion as well as lymphangiogenesis in the tumor microenvironment. Our studies also uncover a relationship between COX-2 and semaphorin 7a expression and suggest that semaphorin 7a promotes tumor cell invasion on collagen and lymphangiogenesis via activation of β 1 -integrin receptor. Our results suggest that semaphorin 7a may be novel target for blocking breast tumor progression.
INTRODUCTION
Semaphorin 7a belongs to a large class of secreted and membrane-bound proteins that were originally identified for their pleiotropic roles in neurite extension and migration. [1] [2] [3] Unlike other semaphorins, which act to stunt axon outgrowth and inhibit angiogenesis, semaphorin 7a enhances axon migration and development [1] [2] [3] and angiogenesis. [4] [5] [6] [7] [8] During neurogenesis, Sem7a promotes cell adhesion and motility through interaction with β 1 -integrin receptors. A similar role for Sem7a in monocyte and melanocyte migration has been described. 9, 10 Furthermore, Sem7a also promotes differentiation in monocytes and osteoblasts. 11, 12 In mice, Sem7a expression is observed at high levels in the brain, spinal cord, lung, testis, bone and spleen as well as in immune cells; in human tissues, Sem7a expression has been observed in the nervous system, odontoblasts, fibroblasts, keratinocytes, endothelial cells and melanocytes. 3, 11, [13] [14] [15] Although Sem7a has been primarily characterized for its role in development, re-activation of developmental programs often occurs during tumorigenesis and the pleiotropic nature of the semaphorins during development has led to the investigation of semaphorins as multi-target therapies for cancer. 16 Recently, in murine mammary tumor models, several studies demonstrated that semaphorin 7a expression promotes mouse mammary tumor cell growth, epithelial to mesenchymal transition, angiogenesis and lung metastasis. 5, 17, 18 However, a role for SEMA7A in human breast tumor progression remains largely unexplored.
To investigate whether Sem7a is a mediator of human breast tumor aggressiveness, we silenced SEMA7A in MCF10DCIS cells. We chose this model based on its unique characteristics, which partially model human ductal carcinoma in situ (DCIS) progression. [19] [20] [21] Briefly, during establishment and outgrowth of the MCF10DCIS.com model, tumor cells create a noninvasive DCIS-like structure that is similar to human DCIS. As early as a week after injection, myoepithelial cells at the radial edges of the DCIS-like structures are evident by expression of myoepithelial markers such as alpha-smooth muscle actin and p63, and deposition of a collagen type 4-positive basement membrane. [20] [21] [22] Increased size of these DCIS-like lesions results from initial proliferation of tumor cells, which have the histologic appearance of microinvasion, but then undergo a differentiation process that creates new DCIS-like neoplastic structures. In a period of approximately 4-8 weeks, all tumors progress to invasive ductal carcinoma (IDC) (Supplementary Figure 1A) that is characterized by tumor cell expression of epithelial to mesenchymal transition markers and fragmentation of the myoepithelial cell layer, underlying basement membranes and 'cancerization' of the associated stroma. 20, 21 During this phase, the neoplastic cells expand rapidly forming confluent sheets of tumor cells that invade directly into the stromal tissue. Within these sheets of invasive cancer, some areas of residual DCIS-like structures may be visible with maintained myoepithelial cells and basement membrane deposition. 20, 21 Interestingly, p63 is initially expressed in peripheral cells of the DCIS-like structures that are morphologically consistent with myoepithelial cells; however, as the tumors in this model progress to an invasive phenotype, p63 is expressed in the majority of the tumor cells. 22, 23 Although this is a consistent feature of this model, it is noted that this is not necessarily consistent with the natural progression of most human ductal carcinomas. 24, 25 We examined the effects of Sem7a silencing on tumor cell growth, motility and invasion in vitro and in vivo; we show that reducing Sem7a expression decreases human breast tumor cell growth, motility, invasion and adhesion. Furthermore, we identify a novel role for Sem7a in promotion of lymphangiogenesis. We also show that Sem7a is regulated by COX-2 expression and that loss of Sem7a from tumor cells reduces tumor cell invasion and activation of the β 1 -integrin receptor. Importantly, our analysis of patient datasets indicates that increased SEMA7A gene expression is observed in a high percentage of human breast tumors and is associated with poor prognosis. Cumulatively, our results suggest that further research into the role of Sem7a in breast cancer may lead to novel therapeutics for patients.
RESULTS

Semaphorin 7a promotes tumor progression in breast cancer patients
To determine whether SEMA7A expression correlates with disease progression in breast cancer patients, we analyzed SEMA7A expression in normal breast tissue compared with IDC in the TCGA dataset 26 using Oncomine. 27 We find that SEMA7A expression is significantly increased in IDC when compared with normal tissue (Figure 1a ). Furthermore, SEMA7A expression was above average in~45% of IDC (red; Figure 1b ). In addition, SEMA7A was above average in 440% of cases in three additional datasets 18, 28, 29 (Table 1) . We also observed the association of SEMA7A with early recurrence, metastasis and death in multiple publically available datasets ( Table 2) . We utilized Kaplan-Meier analysis to determine whether the expression of SEMA7A is associated with poor prognosis in breast cancer patients in the METABRIC (Curtis) 28 breast tumor dataset, which is a large breast cancer dataset that is **** annotated for clinical characteristics and outcomes such as OS and estrogen receptor status. Our analysis revealed decreased OS in patients with increased SEMA7A expression ( Figure 1c ). We also observed that SEMA7A was associated with decreased survival regardless of estrogen receptor status (Figure 1d and Supplementary Figure 1A and B). To further validate that Sem7a is associated with decreased OS, we utilized the gene expressionbased outcome for breast cancer online (GOBO) tool 18 to analyze SEMA7A expression and outcomes in additional breast tumor datasets. In a dataset of 737 tumors, we utilized Kaplan-Meier analysis, shown here as -Log10(p) for OS, to show that high SEMA7A was significantly associated with decreased OS in all breast cancer patients ( Figure 1e ). In addition, a higher proportion of patients with high Sem7a were grade 3 compared with those with low Sem7a (Supplementary Figure 1C ). Taken together, these results implicate SEMA7A in the promotion of tumor metastasis in breast cancer patients, irrespective of the cancer biologic subtype.
SEMA7A expression promotes human tumor cell growth and motility in vitro and in vivo
To determine mechanisms of SEMA7A promotion of breast cancer, we generated MCF10DCIS.com cells with stable silencing of SEMA7A (shSem7a). Decreased Sem7a protein expression was observed (Figure 2a ; Supplementary Figure 2A ). In two independent lines, which harbor different short hairpin (shRNA) sequences, we observed decreased tumor cell growth rate and overall growth when compared with control cells transfected with a non-targeting vector (Figures 2b and c; Supplementary Figure 2B ). We also examined whether Sem7a was required for MCF10DCIS tumor cell growth in three dimensional (3D) culture using our previously described 3D culture system. 23 We observed a decreased number of multicellular spheroids and number of cells/spheroid with shSem7a cells compared with controls ( Figure 2d ; Supplementary Figure 2C ). Furthermore, shSEM7a cells exhibited less mesenchymal morphology ( Figure 2e ) and decreased motility in wound closure assays compared with controls ( Figure 2f ). We also examined the ability of control and knockdown cells to adhere to different matrices and observed that both control and knockdown cells were most adherent and proliferative on fibronectin (Supplementary Figure  2D and E) and that the shSem7a cells were less adherent on all matrices compared with control (Figures 2g and h). These in vitro results suggest that Sem7a promotes breast tumor progression by increasing tumor cell growth and motility.
To determine whether Sem7a promotes breast tumor progression in vivo, we injected shSem7a and control tumor cells into intact nulliparous mouse mammary glands. We observed decreased growth with both KD1 and KD2 (Supplementary Figure 3A ). In a larger study, with shSEM7a KD1 cells, we observed significantly decreased tumor growth ( Figure 3a ), which was maintained even when twice as many shSem7aDCIS KD1 cells were injected ( Figure 3a ). Furthermore, utilizing maximal tumor size (2 cm 3 ) as a surrogate for survival within groups, survival was reduced significantly in the control group compared with the knockdown group ( Figure 3b ). We confirmed that Sem7a protein was decreased in the knockdown group by immunohistochemistry (Supplementary Figure 3B ), but also observed that some of the tumor cells re-gained expression of Sem7a. Nevertheless, we observed decreased Ki67+ nuclei in the shSEM7a tumors suggestive of decreased tumor cell proliferation (Figure 3c ; Supplementary Figure 3C ). We also observed increased cleaved caspase 3 staining in the shSem7a tumors ( Figure 3d ) suggesting that Sem7a promotes tumor cell survival; however, this increase was observed at 2 weeks post injection, but was not confirmed in our 8-week study where Ki67 was still decreased (Supplementary Figure 3D ). Whether this is due to a change in biology or can be attributed to re-expression of Sem7a in vivo is unanswered by our current studies.
To determine invasiveness, lesions that contained only DCIS structures with clearly defined basement membranes and no evidence of microinvasion were scored as 0, lesions that contained DCIS with identifiable micro-invasive foci were scored as 1, lesions that contained significant areas of sheet-like invasive tumor growth mixed with areas of DCIS were scored as 2 and lesions that contained entirely invasive tumor with rare to absent DCIS were scored as 3. While nearly all control tumors were comprised of either mixed DCIS and invasive carcinoma (2) or exclusively invasive carcinoma (3), shSem7a cells produced tumors that were either predominantly DCIS (0-1) or mixed in situ and invasive carcinoma 2 in a manner that appeared dependent on the number of tumor cells injected (Figure 3e ). These results were compiled to create an average invasive score, which was significantly decreased when the same number (200 K) of knockdown cells were injected compared with wild-type controls and trended towards significant when twice as many knockdown cells were injected. Furthermore, when all knockdown tumors were compared with wild-type, there was an overall significant decrease in the invasion score (Supplementary Figure 3E ). Our initial studies examined invasion 4-6 weeks post injection, however, we also examined invasion at a 2 weeks post injection where we observed that 4/4 shSem7a tumors remained DCIS(0) (Supplementary Figure 3F ) while 4/5 controls progressed to microinvasion (1). Therefore, decreased Sem7a expression appears to limit the in vivo invasive potential of the MCF10DCIS.com breast tumor cells. Additional evidence for lack of invasive/mesenchymal phenotype comes from our quantitation of intratumor p63, vimentin and E-cadherin expression (Figures 3f-h); both p63 and vimentin were reduced and E-cadherin increased in the shSem7a tumors suggestive of a less mesenchymal cellular phenotype.
Semaphorin 7a mediates COX-2-dependent tumor cell invasion and promotion of lymphangiogenesis Increases in extracellular collagen 1 can promote COX-2 expression in DCIS.com tumor cells; COX-2 in turn promotes tumor cell growth, invasion and lymphnagiogenesis. 23, 30 To determine whether Sem7a may function downstream of COX-2 to promote growth and invasion, we examined Sem7a expression in shCOX-2 cell lines 23, 30, 31 (Supplementary Figure 4A ). We observed significantly decreased expression of Sem7a in two independent shCOX-2-silenced MCF10DCIS.com cell lines (Figures 4a and b) suggesting that Sem7a expression is dependent upon COX-2 expression. To examine whether Sem7a was a potential mediator of COX-2 dependent invasion on collagen, we analyzed shSem7a cells in our 3D invasion model; as previously reported, we found that the addition of collagen 1 resulted in increased invasion of the control MCF10DCIS.com cells. 23, 32 In contrast, fewer invasive protrusions were observed with the shSem7a cells (Figures 4c and d) . We quantitated % invasive by typing the structures as noninvasive (type 1), partially invasive (type 2) and fully invasive (type 3) (see Supplementary Figure 3B ). Similar to our published results with the shCOX-2 cells, 23 we observed that the majority of structures in the control group were types 2 and 3 while the majority of the structures in the shSem7a group were types 1 and 2 ( Figure 4e ). Because Sem7a promotes dendricity and spreading of neurons and melanocytes through β 1 -integrin receptors, 3, 9 we next investigated whether the activation of β 1 -integrin receptor was altered in 3D structures with shSem7a cells. Using an antibody that specifically recognizes the activated form of β 1 -integrin receptor to stain sections from our 3D invasion studies, 32 we observed higher activation in control structures compared with shSem7a (Figures 4f and g) . Furthermore, the localization of β1-integrin was restricted to the structure periphery in the shSem7a cells, but was observed throughout the structures in the controls (Figure 4f ), suggesting that Sem7a mediates invasion on collagen through the activation of β 1 -integrin receptors. Interestingly, when we block β 1 -integrin receptor in our 3D invasion assay, we did not see decreases in COX-2 expression, but saw decreases in invasive structures. 32 Thus, we propose that COX-2 upregulates Sem7a, which activates β 1 -integrin receptors on neighboring cells to promote tumor cell invasion. Finally, we also observe decreased activation of β 1 -integrin receptor in shSem7a tumors (Figures 4h and i) suggesting that β 1 -integrin receptors mediate MCF10DCIS tumor cell invasion in vivo as well.
Having previously shown that COX-2 mediates lymphangiogenesis in the tumor microenvironment, we also investigated the role of Sem7a in lymphangiogenesis. We added recombinant purified Sem7a to an in vitro lymphangiogenesis assay; PGE 2 was utilized as a positive control for these studies as we have previously published PGE 2 as a pro-lymphangiogenic factor. 30 Compared with controls, we observed a significant increase in the size of in vitro lymphatic structures with addition of Sem7a to levels that were comparable with those observed with PGE2 (Supplementary Figure 3C ). Having also shown that MCF10DCIS tumor cellconditioned media promotes lymphangiogenesis in vitro, 30 we examined the effects of conditioned media from shSEMA7A cells on in vitro lymphangiogenesis. shSEMA7A cell-conditioned media resulted in a significant reduction in lymphatic structure size compared with control, but addition of exogenous Sem7a rescued (Figures 5a and b ). In addition, when we added a function blocking antibody for β 1 -integrin receptor, Sem7a was unable to rescue suggesting that Sem7a also mediates lymphangiogenesis via β 1 -integrin receptor activation (Figure 5c ). Furthermore, in vivo tumor-associated lymphangiogenesis was deceased with shSem7a tumor cells as evidenced by a significant decrease in lymphatic vessel density in the peritumor region of shSem7a tumors (Figures 5d and e; Supplementary Figure 3D ). Finally, in the METABRIC dataset, high Sem7a was associated with increased risk for lymphatic invasion (odds ratio: 2.93, 95% confidence interval: 1.021-8.397, P = 0.0387), which we have previously shown to also be COX-2-dependent 30 (Figure 5f ). Collectively, these in vivo, in vitro and patient-based results suggest that Sem7a exerts pleotropic effects, similar to those induced by COX-2, on tumor cells and the tumor microenvironment to promote breast tumor progression.
DISCUSSION
Sem7a is emerging as an important mediator of melanoma and mammary tumor progression in murine models; 5,18 here, we characterize semaphorin 7a as a novel mediator of breast cancer progression using pre-clinical models of human breast cancer and patient genomic datasets. The results of our studies suggest that Sem7a promotes breast tumor progression via pleiotropic effects on the tumor and tumor-associated lymphatics. Specifically, we demonstrate a novel role for Sem7a in promotion of lymphangiogenesis via activation of β 1 -integrin receptor on lymphatic endothelial cells. Furthermore, we identify a role for of Sem7a in human tumor growth and invasion by proposing a novel mechanism whereby COX-2 expression drives expression of semaphorin 7a. In turn, semaphorin 7a-expressing breast tumor cells promote the activation of β 1 -integrin receptors on neighboring cells to promote invasion ( Figure 6 ). This mechanism is similar to semaphorin 7a promotion of melanocyte migration and neurite extension. 1, 3 Furthermore, although semaphorin 7a has been primarily characterized as a membrane-bound semaphorin, a soluble isoform has been demonstrated 33 and our results also suggest that semaphorin 7a secretion by tumor cells acts directly on the lymphatic endothelium in the tumor microenvironment. In support of this, secretome analysis of glioblastoma cells revealed significantly increased secretion of semaphorin 7a in invasive tumor cells. 34 Importantly, our analyses of multiple tumor datasets suggests that high Sem7a is associated with decreased survival and increased metastasis in breast cancer patients. Furthermore, in three independent datasets, we observe increased expression of SEMA7A in 440% of breast tumors. Thus, a targeted therapy designed to shut down the actions of Sem7a may benefit the large percentage of breast cancer patients predicted by our studies to exhibit increased tumor-associated expression of Sem7a. The question remains of how to properly target Sem7a. Our results revealing that expression is low in normal mammary tissues compared with tumor, along with those of our colleagues showing that Sem7a-null mice are viable, 3 suggest that targeting Sem7a directly may be a therapeutic option. To date, compounds that specifically inhibit Sem7a are unavailable; however, multiple downstream targets of Sem7a have been identified, including FAK and Erk, which are current targets in clinical trials. In addition, our published data showing that extracellular collagen deposition induced upregulation of COX-2 expression can be inhibited with COX-2 inhibitors, 23 coupled with our current observations suggesting that COX-2 expression is necessary for Sem7a expression, make it plausible that COX-2 inhibition may also decrease Sem7a expression. COX-2 inhibitors are relatively safe and readily available. Thus, in the absence of targeted drugs for Sem7a, combination therapies that target downstream effectors and COX-2 could be tested in clinical trials to determine whether tumor progression can be blocked in breast cancer patients with high Sem7a expression. Our results are the first step toward proposing such therapies for breast cancer patients.
MATERIALS AND METHODS
Analysis of publicly available datasets
Oncomine analysis: using SEMA7A as input, we queried all breast tumor datasets. For normal versus tumor analysis analysis (TCGA), we downloaded the data and then utilized GraphPad prism to determine differential expression. For %OE analysis, we determined average expression over the entire dataset and then determined the percentage of the total that were above average. For Metabric (Curtis) dataset analysis, we downloaded the data and cleaned the dataset to include only IDC cases that were sufficiently annotated for survival data and estrogen receptor status (n = 1332). We assessed SEMA7A expression in all subjects and divided them into high or low expression (above or below mean expression in each dataset). We also divided subjects based on estrogen receptor status and high or low SEMA7A expression. Kaplan-Meier analyses were performed in GraphPad Prism. For GOBO analysis: this dataset is compiled from 11 independent, publicly available Affymetrix U133A microarray analyses 18 of human breast tumors; 10-year OS data and Sem7a expression data were available for 737 breast tumors.
Cell culture MCF10DCIS.com-GFP cells (and COX-shRNA derivatives) were obtained from K Polyak and A Marusyk (Harvard). Cells were validated by the DNA sequencing core at the University of Colorado Anschutz Medical Campus and identified to be a pure population of MCF10DCIS cells. Monthly mycoplasma testing confirmed they were negative throughout the studies. Cells were sub-cultured as previously described. 23, 31, 35 Human dermal lymphatic endothelial cells were obtained from PromoCell (Heidelberg, Germany) and maintained according to manufacturer's protocol with the following modifications: for routine culturing, plates were coated with 10 μg/ml Matrigel 30 min prior to plating. 3D cultures were performed as previously described. 23 
RNA isolation
RNA was isolated using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA). Concentration and purity were assessed using absorbance at 280 nm, 260 nm and 230 nm. cDNA was synthesized from 1 μg RNA using the Bio-Rad (Hercules, CA, USA) iScript cDNA Synthesis Kit in the following conditions: 25°C for 5 min, 42°C for 30 min and 85°C for 5 min.
shRNA knockdown Four SureSilencing shRNA plasmids targeting Sema7a and one negative control shRNA (SABiosciences, Frederik, MD, USA) were amplified in E. coli. Plasmid DNA was isolated by Plasmid Maxi-Prep (Qiagen). MCF10DCIS. com-GFP cells were grown overnight in a 24-well dish to 80% confluence. Each Sema7a-specific shRNA plasmid and the negative control shRNA plasmid was diluted to 1 μg/μl in Transfectagro Reduced-Serum Medium (Corning, Corning, NY, USA), and 100 μl of this dilution was incubated for 15 min with 4 μl of X-treme Gene HP DNA transfection reagent (Roche, Basel, Switzerland). This mixture was added dropwise to the cells. Transfected cells were selected for by hygromycin resistance and stable knockdown was confirmed by qPCR. The negative control cells were transfected with a scrambled artificial sequence not matching human, mouse or rat according to the product specification sheet provided by SABiosciences.
qPCR analysis qPCR of cDNA samples was performed using the Bio-Rad iTaq Universal SYBR Green Supermix with primers for SEMA7A (forward: CTCAGCCGTCTGT GTGTATT, reverse: CTCAGGTAGTAGCGAGAGTTTG) and COX-2 (Bio-Rad; PrimePCR). The conditions were as follows: 95°C for 3 min, then 40 cycles of 95°C for 15 s and 60°C for 1 min, 95°C for 30 s and 55°C for 1 min. The fidelity of our primers was assessed after each qPCR reaction using a 95°C melt curve. mRNA quantification was normalized using the geometric average of two reference genes, GAPDH (forward: CAAGAGCACAAGAGGAA GAGAG, reverse: CTACATGGCAACTGTGAGGAG) and RPS18 (forward: GCGAGTACTCAACACCAACA, reverse: GCTAGGACCTGGCTGTATTT).
Western blot analysis
Sem7a western blots were performed by loading equal amounts of protein into each lane. Protein concentration in lysates was determined by Bradford assay. Blots were probed with anti-Sema7a (Atlas, Sockholm, Sweden) or anti-COX2 (Cayman, Ann Arbor, MI, USA) primary antibodies and goat anti-mouse or goat anti-rabbit secondary antibodies (LICOR, Lincoln, NE, USA). Blots were imaged and quantitated on an Odyssey CLx Imager (LICOR).
In vitro growth, proliferation rate, adhesion, and motility assays For proliferation assays, cells were plated at 2000 cells per well of a 96-well dish. Four pictures of different regions in each well were taken every four hours for 48 h using an IncuCyte ZOOM (Essen BioScience, Ann Arbor, MI, USA). Percent confluence was determined using the IncuCyte ZOOM Figure 6 . A model depicting COX-2-mediated Sem7a signaling. We have previously shown that collagen 1 promotes the upregulation of COX-2 through an unknown mechanism. Our current data suggest that COX-2 promotes expression of Sem7a through an unknown mechanism. Sem7a, in turn, promotes tumor cell invasion and lymphangiogenesis via activation of β 1 -integrin receptors on neighboring tumor and lymphatic endothelial cells.
software (Essen BioScience). For motility assays, wells of a 96-well dish were coated with 200 mg/ml matrigel (Corning) and incubated for 2 h at 37°C. Liquid was then aspirated and replaced with 2 mg/ml bovine serum albumin and blocked for 1 h at 37°C. Wells were then washed once with phosphate-buffered saline and cells were plated to produce a uniform monolayer 24 h later. A WoundMaker (Essen BioScience) was used to make scratches across each well. Scratches were cleaned by washing wells two times with phosphate-buffered saline. Pictures were taken at the center of the scratch every hour for 30 h, and the IncucyteZOOM software was used to measure percent wound closure over time. For adhesion assays, cells were plated at 5000 cells/well in a 96-well dish. Six hours post plating, the plates were washed with phosphate-buffered saline and the cells were fixed in 10% neutral buffered formalin before being stained with 10% crystal violet. Images of each well were taken for analysis of positive pixels using ImageJ. 
In vitro lymphangiogenesis assays
Histologic analysis
Tumors were harvested at 2 or between between 4.5 and 7 weeks. Mammary glands (tumors intact) were prepared for hematoxylin and eosin and immunohistochemistry as described. 23 Hematoxylin and eosin-stained sections of tumors were examined by a board-certified anatomic pathologist (AN) blinded to the experimental group. Interpretations of in situ versus invasion were made primarily on the grounds of morphologic phenotype observed on hematoxylin and eosin sections, with p63 immunohistochemistry used to clarify and confirm these conclusions in challenging cases. Those lesions which contained only well-developed DCIS structures with clearly defined basement membranes and no evidence of microinvasion were scored as 0. Lesions that contained extensive DCIS with easily identifiable micro-invasive foci were scored as 1.
Lesions that contained significant areas of sheet-like invasive tumor growth admixed with areas of DCIS were scored as 2. Finally, lesions that contained entirely invasive tumor with rare to absent DCIS remnants were scored as 3.
Immunohistochemistry
Antibody information is provided in Supplementary Table 1 . Quantification of total tumor area (necrotic and stromal areas removed) and percent positive stain was performed using Image Aperio Analysis software (Leica, Buffalo Grove, IL, USA). Briefly, entire histological sections were imaged with Aperio ScanCope T3 scanner at 0.47 microns per pixel. The images were then down-sampled to a resolution of 1.5 microns per pixel to facilitate subsequent image manipulation. Areas for quantification were annotated using Aperio analysis tools and percent weak, medium and strong determined using the color-deconvolution tool. For Ki67 and p63+, the denominator is total nuclei; for vimentin and E-cadherin; the denominator is total tumor area.
Experimental replicates, sample size and statistical analyses
For all in vitro studies, individual experiments were performed in triplicate and each experiment replicated three times. Representative data from a single experiment are shown for all in vitro studies. For animal studies, we chose the number of mice/cell line/group/time-point based on power calculations from previous and pilot studies to achieve 80% or more power (β), with α = 0.05 (two-sided). For all animal studies, each tumor is represented by a dot on the graph to indicate the exact number of tumors per group. All animal studies were replicated twice with representative or pooled data shown. Aside from instances of unexpected death or cell contamination, no samples or animals were excluded from our analysis. Unpaired t-test (two-sided), Chi-square, Log-rank (Mantel-Cox), Gehan-Breslow-Wilcoxon and Pearson correlations were performed in GraphPad Prism, assuming independent samples and normal distributions. Only P-values less than 0.05 were considered significant.
